drugset
drugset / Trial / NCT06585241

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

NCT06585241 ↗

Phase 4 Recruiting 1144 enrolled ModernaTX, Inc.
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Timeline

Start
2024-09-09
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject mRNA-1273 Variant-containing Formulation Messenger RNA (mRNA) — Intramuscular

Indications

COVID-19